Analysts expect that Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) will post ($0.73) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Checkmate Pharmaceuticals’ earnings. Checkmate Pharmaceuticals reported earnings per share of ($0.65) during the same quarter last year, which would suggest a negative year-over-year growth rate of 12.3%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that Checkmate Pharmaceuticals will report full-year earnings of ($3.15) per share for the current fiscal year, with EPS estimates ranging from ($3.24) to ($3.05). For the next financial year, analysts expect that the company will post earnings of ($2.83) per share, with EPS estimates ranging from ($4.11) to ($1.55). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Checkmate Pharmaceuticals.
In other news, major shareholder Global Strategic Fund I. Venbio sold 69,230 shares of the firm’s stock in a transaction on Friday, April 29th. The shares were sold at an average price of $10.38, for a total value of $718,607.40. Following the sale, the insider now owns 2,805,833 shares in the company, valued at $29,124,546.54. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Global Strategic Fund I. Venbio sold 47,396 shares of the firm’s stock in a transaction on Wednesday, April 27th. The stock was sold at an average price of $10.38, for a total transaction of $491,970.48. Following the completion of the sale, the insider now owns 2,948,463 shares in the company, valued at approximately $30,605,045.94. The disclosure for this sale can be found here. In the last three months, insiders sold 608,537 shares of company stock worth $6,316,970. Insiders own 6.30% of the company’s stock.
A hedge fund recently bought a new stake in Checkmate Pharmaceuticals stock. Millennium Management LLC purchased a new stake in Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 10,633 shares of the company’s stock, valued at approximately $31,000. 74.56% of the stock is owned by hedge funds and other institutional investors.
Shares of CMPI opened at $10.38 on Friday. The firm’s 50 day moving average price is $4.37 and its 200 day moving average price is $3.66. Checkmate Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $10.48.
Checkmate Pharmaceuticals Company Profile (Get Rating)
Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.
- Get a free copy of the StockNews.com research report on Checkmate Pharmaceuticals (CMPI)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.